| Authors: |
Conteduca V; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Ku SY; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Fernandez L; Epic Sciences, Inc., San Diego, CA, USA., Dago-Rodriquez A; Epic Sciences, Inc., San Diego, CA, USA., Lee J; Epic Sciences, Inc., San Diego, CA, USA., Jendrisak A; Epic Sciences, Inc., San Diego, CA, USA., Slade M; Epic Sciences, Inc., San Diego, CA, USA., Gilbertson C; Epic Sciences, Inc., San Diego, CA, USA., Manohar J; Weill Cornell Medicine, New York, NY, USA., Sigouros M; Weill Cornell Medicine, New York, NY, USA., Wang Y; Epic Sciences, Inc., San Diego, CA, USA., Dittamore R; Epic Sciences, Inc., San Diego, CA, USA., Wenstrup R; Epic Sciences, Inc., San Diego, CA, USA., Mosquera JM; Weill Cornell Medicine, New York, NY, USA., Schonhoft JD; Epic Sciences, Inc., San Diego, CA, USA., Beltran H; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. himisha_beltran@dfci.harvard.edu.; Weill Cornell Medicine, New York, NY, USA. himisha_beltran@dfci.harvard.edu. |